PerformanceRiskValuationProfitabilityCashflowLiquidityESGRevenue & Geographic ExposureForecastFinancial GrowthIncome GrowthCashflow GrowthBalance Sheet Growth
Actinium Pharmaceuticals, Inc. (ATNM)
1.780.01 (-0.56%)
1.75 - 1.81
1.03 - 2.41
122.5K / 296.7K (Avg.)
-1.36 | -1.31
Gauges a company's financial stability and solvency. Value investors pay close attention to leverage and liquidity risk, ensuring the company has enough cushion to withstand downturns without impairing shareholder value.
0.29
D/E ratio exceeding 1.5x Biotechnology median of 0.00. Howard Marks would check for debt covenant compliance and refinancing risks.
1.49
Net debt aligned with Biotechnology median of 1.37. David Dodd would verify if industry standard leverage is appropriate given business cyclicality.
No Data
No Data available this quarter, please select a different quarter.
1.75
Current ratio below 50% of Biotechnology median of 3.98. Michael Burry would check for immediate refinancing needs.
No Data
No Data available this quarter, please select a different quarter.